ACS medicinal chemistry letters · 2017
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Michaelides Michael R, Kluge Arthur, Patane Michael, Van Drie John H, Wang Ce, Hansen T Matthew, Risi Roberto M, Mantei Robert, Hertel Carmen, Karukurichi Kannan, Nesterov Alexandre, McElligott David, de Vries Peter, Langston J William, Cole Philip A, Marmorstein Ronen, Liu Hong, Lasko Loren, Bromberg Kenneth D, Lai Albert, Kesicki Edward A
Аннотация
p300 and its paralog CBP can acetylate histones and other proteins and have been implicated in a number of diseases characterized by aberrant gene activation, such as cancer. A novel, highly selective, orally bioavailable histone acetyltransferase (HAT) domain inhibitor has been identified through virtual ligand screening and subsequent optimization of a unique hydantoin screening hit. Conformational restraint in the form of a spirocyclization followed by substitution with a urea led to a significant improvement in potency. Replacement of the hydantoin moiety with an oxazolidinedione followed by fluoro substitution led to A-485, which exhibits potent cell activity, low clearance, and high oral bioavailability.